Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?
about
An Update on Inflamm-Aging: Mechanisms, Prevention, and TreatmentThe role of phosphodiesterase-5 inhibitors in prostatic inflammation: a reviewMesenchymal stem cells as a vector for the inflammatory prostate microenvironmentProstatic inflammation induces fibrosis in a mouse model of chronic bacterial infectionInterleukin-18 may lead to benign prostatic hyperplasia via thrombospondin-1 production in prostatic smooth muscle cellsAnti-inflammatory activity of soy and tea in prostate cancer preventionStromal response to prostate cancer: nanotechnology-based detection of thioredoxin-interacting protein partners distinguishes prostate cancer associated stroma from that of benign prostatic hyperplasiaCustom 4-Plex DiLeu Isobaric Labels Enable Relative Quantification of Urinary Proteins in Men with Lower Urinary Tract Symptoms (LUTS)The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial.Serum antibodies against genitourinary infectious agents in prostate cancer and benign prostate hyperplasia patients: a case-control studyProteomic analysis of patient tissue reveals PSA protein in the stroma of benign prostatic hyperplasia.Effects of pulsed electromagnetic fields on benign prostate hyperplasia.Obesity-induced diabetes and lower urinary tract fibrosis promote urinary voiding dysfunction in a mouse modelSurgical intervention for symptomatic benign prostatic hyperplasia is correlated with expression of the AP-1 transcription factor networkCharacterization of subepithelial interstitial cells in normal and pathological human prostate.CXC-type chemokines promote myofibroblast phenoconversion and prostatic fibrosis.Dietary, but not supplemental, intakes of carotenoids and vitamin C are associated with decreased odds of lower urinary tract symptoms in men.Chronic prostatic infection and inflammation by Propionibacterium acnes in a rat prostate infection model.Mechanisms of synergism between antagonists of growth hormone-releasing hormone and antagonists of luteinizing hormone-releasing hormone in shrinking experimental benign prostatic hyperplasia.Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasiaNonsteroidal antiinflammatory drug use and lower urinary tract symptoms: results from the Boston area community health survey.Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH).Chemokines and BPH/LUTSChemopreventive effects of tea in prostate cancer: green tea versus black tea.The functional role of reactive stroma in benign prostatic hyperplasia.Influence of E. coli-induced prostatic inflammation on expression of androgen-responsive genes and transforming growth factor beta 1 cascade genes in ratsAcute bacterial inflammation of the mouse prostate.Effect of Silodosin, an Alpha1A-Adrenoceptor Antagonist, on Ventral Prostatic Hyperplasia in the Spontaneously Hypertensive Rat.Association of overactive bladder and C-reactive protein levels. Results from the Boston Area Community Health (BACH) Survey.Increased infiltrated macrophages in benign prostatic hyperplasia (BPH): role of stromal androgen receptor in macrophage-induced prostate stromal cell proliferationDetection of Trichomonas vaginalis in prostate tissue and serostatus in patients with asymptomatic benign prostatic hyperplasia.Quantification of Arachidonic Acid and Its Metabolites in Rat Tissues by UHPLC-MS/MS: Application for the Identification of Potential Biomarkers of Benign Prostatic HyperplasiaDiagnostic accuracy of urinary prostate protein glycosylation profiling in prostatitis diagnosis.Effects of flavocoxid, a dual inhibitor of COX and 5-lipoxygenase enzymes, on benign prostatic hyperplasia.Acupuncture for benign prostatic hyperplasia: A systematic review and meta-analysis.Prostatic diseases under focus in a university hospital in Eastern Saudi Arabia. A 15-year experience.Inflammation and benign prostatic hyperplasia.Indications for and use of nonsteroidal antiinflammatory drugs and the risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trialAssociation of C-reactive protein and lower urinary tract symptoms in men and women: results from Boston Area Community Health survey.NF-κB and androgen receptor variant expression correlate with human BPH progression
P2860
Q26738759-B01EDD64-4030-41F0-82F6-4769DF01BCB3Q26785428-B7557184-A109-4DC2-8EE9-0A9F5CA5FABBQ26853374-4777DBD4-2D07-4074-8DE3-A7860D3C06CDQ27321863-F89614A7-13A6-4741-B9B9-A66291E889CCQ28118871-0B2964F1-CCD9-47DE-98AF-EEF142CEA66AQ28391888-B2E857AC-DA66-4DD7-A5ED-2C499DB36683Q28533720-AA14FE02-29E6-4D98-8F9D-6E85BC0F4FC6Q28547212-19DE4528-8410-4761-9AEE-252F348112B7Q31137576-5ED9FFB6-4351-4C2A-AB0B-361B93A02D8CQ33811238-E8BC6CAE-5FBE-4C34-86A4-457986104345Q33827627-DAE73C66-2CA9-4EF1-8E5E-AE26410AC689Q33888056-794266F1-E9A2-4816-8890-02CADE1B90E3Q33908275-53E92549-3AEB-4FE1-877C-B591601D324DQ34163024-B25FB3CF-8CC1-4FAD-A1B3-E91326E92D0BQ34406931-4756AAFA-A8A5-4C88-A66E-BE2C39F0D225Q34485215-D74EC902-6916-4CD5-9A73-1CEEEE3F339CQ34493142-68D846BF-E0BD-4408-83F3-336EF909A106Q34512368-546DF74D-7D6C-4CF8-860C-0D7F5D92A946Q34529072-754D701D-8366-42E6-A47A-7E6FCC1512A7Q34621536-10396E08-1762-460F-849E-88D6946BB0EFQ35062696-66A3A512-75B2-48D7-8968-BCA3BD41C0C9Q35089850-35DBDC68-D906-4864-8CD9-936B046022A9Q35179438-A7CC99F5-8943-4D72-9B22-031B4FDE8558Q35185534-9A415BB7-ACBF-4727-878A-217FD6B3F72BQ35231687-29F9CEEB-296C-4A9F-B119-92DA4FFCA281Q35468651-6E359BD2-F514-43AA-9871-1A3A6BE52E3CQ35661399-E3A7495B-CB00-4A08-8F95-AD3C830D1FF5Q35755940-410E964B-8C9A-4E34-9B6C-81D15C4B2AFBQ35886128-360DEE83-F941-4EB5-B0A1-0FA7C6C75036Q36003050-4E495871-4472-493A-A16A-2CD334F173A5Q36142110-EAA2E565-53FE-43AD-9764-58304AC4E86AQ36205437-B40F2D37-9209-4A7F-A078-38250512FC59Q36211911-AB11B472-F030-47F1-8CFA-84DDF762DF9FQ36252843-24D6B4A9-1B0C-4E89-B184-B86584F52CF8Q36334184-00F64E78-44B9-405D-B108-B890E7C26A37Q36356637-0D6CF6ED-9DE6-4786-A660-0EF7C2C72DF0Q36380033-A15168A3-D423-4B6A-969C-A2E9E76C6DAEQ36383682-09422B19-A8CE-4C32-8EDC-959172FD8EB5Q36550992-BDE169B2-0184-4B77-9D99-A1136A4CD33CQ36606285-A12D2EBA-01E8-461E-A4E5-175595918397
P2860
Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?
@ast
Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?
@en
type
label
Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?
@ast
Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?
@en
prefLabel
Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?
@ast
Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?
@en
P2093
P1433
P1476
Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?
@en
P2093
Dieter Mitteregger
Gero Kramer
Michael Marberger
P304
P356
10.1016/J.EURURO.2006.12.011
P407
P577
2006-12-11T00:00:00Z